This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Anti-EGFr/CD89 Antibody
Description: MDX-214 is believed to target the epidermal growth factor receptor (EGFr). Preclinical in vitro studies suggest that MDX-214 may provide an unusually potent approach to treating EGFr-positive cancers by inhibiting tumor cell growth and by mediating antibody-dependent cellular cytotoxicity (ADCC).
Deal Structure: MDX-214 was originally developed by Medarex.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The acquisition was closed in September 2009.
Additional information available to subscribers only: